StockData
Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc. (HRTX) stock

HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$0.25−0.01 (-4.39%)

Close on Nov 20, 2026Market cap $47.94MP/E –Yield –

Heron Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Heron Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$12.14M. For fiscal 2025 it was -$27.91M. The highest annual figure on record is -$5.56M in fiscal 2010.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$27.91M–
FY2024Dec 31, 2024-$24.24M–
FY2023Dec 31, 2023-$60.33M–
FY2022Dec 31, 2022-$148.74M–
FY2021Dec 31, 2021-$206.38M–
FY2020Dec 31, 2020-$191.63M–
FY2019Dec 31, 2019-$131.73M–
FY2018Dec 31, 2018-$200.98M–
FY2017Dec 31, 2017-$172.85M–
FY2016Dec 31, 2016-$137.23M–
FY2015Dec 31, 2015-$79.61M–
FY2014Dec 31, 2014-$61.72M–
FY2013Dec 31, 2013-$42.45M–
FY2012Dec 31, 2012-$17.98M–
FY2011Dec 31, 2011-$8.23M–
FY2010Dec 31, 2010-$5.56M–
FY2009Dec 31, 2009-$11.00M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.35M–
Q1 FY2026Mar 31, 2026-$1.93M–
Q4 FY2025Dec 31, 2025-$9.18M–
Q3 FY2025Sep 30, 2025$1.33M-54.7%
Q2 FY2025Jun 30, 2025-$11.08M-602.3%
Q1 FY2025Mar 31, 2025-$8.98M–
Q4 FY2024Dec 31, 2024-$12.42M–
Q3 FY2024Sep 30, 2024$2.94M–
Q4 FY2023Dec 31, 2023$2.21M–
Q3 FY2023Sep 30, 2023-$9.97M–
Q2 FY2023Jun 30, 2023-$27.44M–
Q1 FY2023Mar 31, 2023-$25.12M–
Q4 FY2022Dec 31, 2022-$37.95M–
Q3 FY2022Sep 30, 2022-$37.11M–
Q2 FY2022Jun 30, 2022-$28.70M–
Q1 FY2022Mar 31, 2022-$44.98M–
Q4 FY2021Dec 31, 2021-$45.65M–
Q3 FY2021Sep 30, 2021-$54.70M–
Q2 FY2021Jun 30, 2021-$63.31M–
Q1 FY2021Mar 31, 2021-$42.72M–
Q4 FY2020Dec 31, 2020-$55.05M–
Q3 FY2020Sep 30, 2020-$42.69M–
Q2 FY2020Jun 30, 2020-$58.03M–
Q1 FY2020Mar 31, 2020-$35.87M–
Q4 FY2019Dec 31, 2019-$30.88M–
Q3 FY2019Sep 30, 2019-$24.42M–
Q2 FY2019Jun 30, 2019-$25.27M–
Q1 FY2019Mar 31, 2019-$51.16M–
Q4 FY2018Dec 31, 2018-$36.96M–
Q3 FY2018Sep 30, 2018-$39.33M–
Q2 FY2018Jun 30, 2018-$62.06M–
Q1 FY2018Mar 31, 2018-$62.62M–
Q4 FY2017Dec 31, 2017-$48.28M–
Q3 FY2017Sep 30, 2017-$40.54M–
Q2 FY2017Jun 30, 2017-$32.52M–
Q1 FY2017Mar 31, 2017-$51.52M–
Q4 FY2016Dec 31, 2016-$39.21M–
Q3 FY2016Sep 30, 2016-$36.65M–

More Heron Therapeutics figures

See a number that looks wrong?